相关临床试验
48
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1949
已完成
22
45.8%
尚未招募
6
12.5%
招募中
14
29.2%
暂停
1
2.1%
Unknown
5
10.4%
暂无批准数据
- Researchers at Kindai University, RIKEN and collaborators found that roughly 5% of clear cell ovarian cancers display unusually high IL-17 activity, creating an inflammatory, immunotherapy-permissive microenvironment. - IL-17 acts directly on cancer cells, activating NF-κB to release chemokines that recruit functional antitumor immune cells, independent of microsatellite instability or high tumor mutational burden. - In mouse models, an IL-17-rich environment made anti-PD-L1 checkpoint therapy more effective and extended survival, suggesting IL-17 is a predictive rather than prognostic biomarker. - The findings, published in Molecular Cancer, point toward personalized selection of immunotherapy for a subtype long considered resistant to both chemotherapy and checkpoint blockade.
- A Phase 2 trial of L-arginine in Spinocerebellar Ataxia type 6 (SCA6) showed a trend toward symptom improvement, but the results did not reach statistical significance. - The L-arginine group experienced a 0.96-point improvement in SARA scores, while the placebo group worsened by 0.56 points over 48 weeks. - Two serious adverse events potentially linked to L-arginine were reported, including one fatality due to pneumonia and one case of reversible liver impairment. - Further Phase 3 trials with larger cohorts are needed to confirm L-arginine's efficacy and safety in treating SCA6, a neurodegenerative disorder.
